Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe. Issue 8 (11th February 2022)

• Record Type: Journal Article
• Authors: Seidl, Elias; Schwerk, Nicolaus; Carlens, Julia; Wetzke, Martin; Cunningham, Steve; Emiralioğlu, Nagehan; Kiper, Nural; Lange, Joanna; Krenke, Katarzyna; Ullmann, Nicola; Krikovszky, Dora; Maqhuzu, Phillen; Griese, Charlotte A; Schwarzkopf, Larissa; Griese, Matthias
• Is Part Of: Thorax. Volume 77:Issue 8(2022)
• Page Start: 781
• Page End: 789
• Publication Date: 2022-02-11
• Subjects: paediatric interstitial lung disease -- paediatric lung disaese; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2021-217751
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Background: No data on healthcare utilisation and associated costs for the many rare entities of children's interstitial lung diseases (chILD) exist. This paper portrays healthcare utilisation structures among individuals with chILD, provides a pan-European estimate of a 3-month interval per-capita costs and delineates crucial cost drivers. Methods: Based on longitudinal healthcare resource utilisation pattern of 445 children included in the Kids Lung Register diagnosed with chILD across 10 European countries, we delineated direct medical and non-medical costs of care per 3-month interval. Country-specific utilisation patterns were assessed with a children-tailored modification of the validated FIMA questionnaire and valued by German unit costs. Costs of care and their drivers were subsequently identified via gamma-distributed generalised linear regression models. Results: During the 3 months prior to inclusion into the registry (baseline), the rate of hospital admissions and inpatient days was high. Unadjusted direct medical per capita costs (€19 818) exceeded indirect (€1 907) and direct non-medical costs (€1 125) by far. Country-specific total costs ranged from €8 713 in Italy to €28 788 in Poland. Highest expenses were caused by the disease categories 'diffuse parenchymal lung disease (DPLD)-diffuse developmental disorders' (€45 536) and 'DPLD-unclear in the non-neonate' (€47 011). During a follow-up time of up to 5 years, direct medical costs dropped, whereas indirect costs and non-medical costs remained stable. Conclusions: This is the first prospective, longitudinal study analysing healthcare resource utilisation and costs for chILD across different European countries. Our results indicate that chILD is associated with high utilisation of healthcare services, placing a substantial economic burden on health systems.